CG Oncology Names Isabel Kalofonos as Chief Commercial Officer Ahead of Potential Launch
CG Oncology, Inc. (NASDAQ:CGON) announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Kalofonos brings over 20 years of biopharmaceutical commercial leadership experience, having previously served in Chief Commercial Officer roles at Crinetics Pharmaceuticals and ImmunoGen, as well as executive positions at Galderma and Takeda Pharmaceuticals.
The executive appointment comes as CG Oncology prepares for the potential first commercial launch of cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for non-muscle invasive bladder cancer. Bringing on an experienced commercial leader is part of the company's strategy to build out its commercial operations and execution capabilities.
Investors will be watching the ongoing clinical development of cretostimogene, which is currently in Phase 3 studies including BOND-003 and PIVOT-006. Any future commercial release remains dependent on regulatory review and approval by health authorities.
Key points
- CG Oncology, Inc. (NASDAQ:CGON) appointed Isabel Kalofonos as Chief Commercial Officer.
- Kalofonos brings over 20 years of biopharmaceutical experience, including previous CCO roles at Crinetics Pharmaceuticals and ImmunoGen.
- The hire supports CG Oncology's commercial strategy ahead of a potential launch for its bladder cancer treatment, cretostimogene grenadenorepvec.
- Cretostimogene is currently being evaluated in Phase 3 clinical trials, BOND-003 and PIVOT-006.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Who is CG Oncology's new Chief Commercial Officer?
CG Oncology appointed Isabel Kalofonos as Chief Commercial Officer. She has over 20 years of biopharmaceutical commercial experience and previously served as CCO at Crinetics Pharmaceuticals and ImmunoGen.
What drug is CG Oncology preparing to launch?
CG Oncology is preparing for the potential commercial launch of cretostimogene grenadenorepvec, an investigational therapy for non-muscle invasive bladder cancer.
What clinical trials is CG Oncology conducting for cretostimogene?
Cretostimogene is being evaluated in Phase 3 trials BOND-003 and PIVOT-006, as well as Phase 2 trial CORE-008, for non-muscle invasive bladder cancer.